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Fall prevention with supplemental and active forms of vitamin
D: a meta-analysis of randomised controlled trials
Abstract
OBJECTIVE: To test the efficacy of supplemental vitamin D and active forms of vitamin D with or
without calcium in preventing falls among older individuals. DATA SOURCES: We searched Medline,
the Cochrane central register of controlled trials, BIOSIS, and Embase up to August 2008 for relevant
articles. Further studies were identified by consulting clinical experts, bibliographies, and abstracts. We
contacted authors for additional data when necessary. Review methods Only double blind randomised
controlled trials of older individuals (mean age 65 years or older) receiving a defined oral dose of
supplemental vitamin D (vitamin D(3) (cholecalciferol) or vitamin D(2) (ergocalciferol)) or an active
form of vitamin D (1alpha-hydroxyvitamin D(3) (1alpha-hydroxycalciferol) or 1,25-dihydroxyvitamin
D(3) (1,25-dihydroxycholecalciferol)) and with sufficiently specified fall assessment were considered
for inclusion. RESULTS: Eight randomised controlled trials (n=2426) of supplemental vitamin D met
our inclusion criteria. Heterogeneity among trials was observed for dose of vitamin D (700-1000 IU/day
v 200-600 IU/day; P=0.02) and achieved 25-hydroxyvitamin D(3) concentration (25(OH)D
concentration: <60 nmol/l v >or=60 nmol/l; P=0.005). High dose supplemental vitamin D reduced fall
risk by 19% (pooled relative risk (RR) 0.81, 95% CI 0.71 to 0.92; n=1921 from seven trials), whereas
achieved serum 25(OH)D concentrations of 60 nmol/l or more resulted in a 23% fall reduction (pooled
RR 0.77, 95% CI 0.65 to 0.90). Falls were not notably reduced by low dose supplemental vitamin D
(pooled RR 1.10, 95% CI 0.89 to 1.35; n=505 from two trials) or by achieved serum 25-hydroxyvitamin
D concentrations of less than 60 nmol/l (pooled RR 1.35, 95% CI 0.98 to 1.84). Two randomised
controlled trials (n=624) of active forms of vitamin D met our inclusion criteria. Active forms of vitamin
D reduced fall risk by 22% (pooled RR 0.78, 95% CI 0.64 to 0.94). CONCLUSIONS: Supplemental
vitamin D in a dose of 700-1000 IU a day reduced the risk of falling among older individuals by 19%
and to a similar degree as active forms of vitamin D. Doses of supplemental vitamin D of less than 700
IU or serum 25-hydroxyvitamin D concentrations of less than 60 nmol/l may not reduce the risk of
falling among older individuals.
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ABSTRACT
Objective To test the efficacy of supplemental vitamin D
and active forms of vitamin D with or without calcium in
preventing falls among older individuals.
Data sourcesWe searched Medline, the Cochrane central
register of controlled trials, BIOSIS, and Embase up to
August 2008 for relevant articles. Further studies were
identified by consulting clinical experts, bibliographies,
and abstracts. We contacted authors for additional data
when necessary.
ReviewmethodsOnly double blind randomised controlled
trials of older individuals (mean age 65 years or older)
receiving a defined oral dose of supplemental vitamin D
(vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol))
or an active form of vitamin D (1α-hydroxyvitamin D3 (1α-
hydroxycalciferol) or 1,25-dihydroxyvitamin D3 (1,25-
dihydroxycholecalciferol)) and with sufficiently specified
fall assessment were considered for inclusion.
Results Eight randomised controlled trials (n=2426) of
supplemental vitamin D met our inclusion criteria.
Heterogeneity among trials was observed for dose of
vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02)
and achieved 25-hydroxyvitamin D3 concentration (25
(OH)D concentration: <60 nmol/l v ≥60 nmol/l; P=0.005).
High dose supplemental vitamin D reduced fall risk by
19% (pooled relative risk (RR) 0.81, 95% CI 0.71 to 0.92;
n=1921 from seven trials), whereas achieved serum 25
(OH)D concentrations of 60 nmol/l or more resulted in a
23% fall reduction (pooled RR 0.77, 95% CI 0.65 to 0.90).
Falls were not notably reduced by low dose supplemental
vitamin D (pooled RR 1.10, 95% CI 0.89 to 1.35; n=505
from two trials) or by achieved serum25-hydroxyvitaminD
concentrations of less than 60 nmol/l (pooled RR 1.35,
95% CI 0.98 to 1.84). Two randomised controlled trials
(n=624) of active forms of vitamin D met our inclusion
criteria. Active forms of vitamin D reduced fall risk by 22%
(pooled RR 0.78, 95% CI 0.64 to 0.94).
Conclusions Supplemental vitamin D in a dose of 700-
1000 IU a day reduced the risk of falling among older
individuals by 19%and to a similar degree as active forms
of vitaminD. Doses of supplemental vitaminDof less than
700 IU or serum 25-hydroxyvitamin D concentrations of
less than 60 nmol/l may not reduce the risk of falling
among older individuals.
INTRODUCTION
Each year one in three people aged 65 years or older
experiences at least one fall,1-3 with 9% of falls leading
to an emergency room visit and 5-6% resulting in a
fracture.4 Fall preventionhas, therefore, becomeapub-
lic health goal, especially as the older proportion of the
population grows.
Vitamin D has direct effects on muscle strength
modulated by specific vitamin D receptors present in
humanmuscle tissue.5 6Myopathy from severe vitamin
D deficiency presents as muscle weakness and pain,7
but is reversible with vitamin D supplementation.6 In
several trials of older individuals at risk for vitamin D
deficiency, vitamin D supplementation improved
strength, function, and balance in a dose-related
pattern.4 8 9 Most importantly, these benefits translated
into a reduction in falls.4 8 9
Overall, however, results have been mixed for fall
prevention with vitamin D; for example, several trials
of vitaminDhavehadnon-significant results. Thismay
be explained in part by the use of low doses of vitamin
D, as suggested by a 2004meta-analysis of limited data
from three trials on supplemental vitamin D.10 Other
potential explanations include the availability of vita-
minDover the counter for the control group; the use of
an open trial design, which biases trial results towards
the null11; and incomplete assessment, inadequate defi-
nition, or incomplete ascertainment of falls during the
entire observation period,12 again introducing a bias
towards the null.
Several trials on vitamin D have been performed
since 2004; thus, the importance of vitamin D dose
for the prevention of falls should be reassessed. Speci-
fically, we need to establish the optimum threshold of
serum 25-hydroxyvitamin D3 (25(OH)D; calcidiol
(25-hydroxycholecalciferol)) required to prevent falls
in older individuals. Notably, two epidemiology stu-
dies among older individuals have found a dose-
response relationship between lower extremity func-
tion and serum 25(OH)D concentrations,13 14 with
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one study identifying a threshold of 50 nmol/l for
optimal function.13 The other larger study found that
function continued to improvewith increasing concen-
tration, without any plateau.14
Both active forms of vitamin D and standard supple-
mental vitamin D have been suggested to prevent falls
among older individuals, but no direct comparison of
these two groups is available. Active forms of vitaminD
do not need hydroxylation in the kidney, so their effect
on falls should be influenced less by age related decline
in kidney function than the effect of supplemental vita-
min D. However, active forms of vitamin D cost more
and are associatedwith a higher risk for hypercalcaemia
than standard supplemental vitamin D.
The aim of this meta-analysis was to assess the effi-
cacy of vitamin D supplementation, with and without
calcium, for the prevention of falls among older per-
sons by dose and serum concentration of 25(OH)D
achieved. In addition,we assessed the efficacy of active
forms of vitamin D compared with supplemental vita-
min D in the prevention of falls.
METHODS
Search strategy and data extraction
We conducted a systematic search for all English and
non-English articles in Medline (Ovid, Pubmed) and
the Cochrane central register of controlled trials from
January 1960 to August 2008, in BIOSIS from January
1985 to July 2008, and inEmbase from January 1991 to
August 2008. Additional studies were identified by
contacting experts, searching reference lists, and
searching abstracts presented at the American Society
for Bone andMineral Research from1995 to 2008.We
used Medical Subject Headings (MeSH) as search
terms, including terms related to trials (“randomised
controlled trial,” “controlled clinical trial,” “random
allocation,” “double-blind method,” and “single-blind
method”), vitamin D (“cholecalciferol,” “hydroxy-
cholecalciferol,” “calcifediol,” “ergocalciferol,” “calci-
diol,” “vitamin D/blood/25-hydroxyvitamin D,”
“1,25-dihydroxyvitamin D,” “1-α-hydroxyvitamin
D,” “1-alpha-hydroxyvitaminD,” “calcitriol,” “alfacal-
cidol,” and “paricalcitol”), and falls (“falls,” “accidental
falls,” “fall prevention,” and “balance”), and the terms
“humans,” “elderly,” and “bone density.” Data extra-
ction was conducted independently by two authors
(HAB-F and JH). A consensus procedure was devel-
oped but was not necessary because of concordance.
Inclusion criteria
Randomised controlled trials of fall prevention with a
defined oral dose of supplemental vitamin D (vitamin
D3 (cholecalciferol) or vitamin D2 (ergocalciferol))
or oral active vitamin D (1α-hydroxyvitamin D3
(1α-hydroxycalciferol) or 1,25-dihydroxyvitamin D3
(1,25-dihydroxycholecalciferol)) in individuals aged
65 years or older with a minimum follow-up of three
months were identified. To be included in the primary
analysis, the trial design had to be double blind and the
assessment of falls sufficiently specified according to
the following criteria: (a) falls had to be a primary or
secondary end point defined at the onset of the trial;
(b) the study had to include a definition of falls and
how they were assessed; and (c) falls had to be assessed
for the entire trial period. Eligible studies that did not
meet the criteria for the primary analysiswere included
in a sensitivity analysis, such as studies involving older
patients in an unstable health state (that is, those
recruited during acute inpatient care).
We excluded reviews, trials that were not rando-
mised, trials that did not include a control group, obser-
vational studies, and animal studies. Given that health
conditions that place patients at high risk for fallsmight
mask the benefits of vitamin D on falls, we excluded
studies that focused on patients with Parkinson’s dis-
ease, organ transplant recipients, or patients with
stroke. We excluded trials that assessed intramuscular
injection of vitamin D because this technique is inva-
sive and has resulted in small but variable increases in
25(OH)D concentrations.15
Outcome measures
Our primary outcome measure was the relative risk of
having at least one fall among persons receiving vita-
min D with or without calcium compared with the risk
among those individuals receiving placebo or calcium
supplementation alone. We analysed separately the
effect of supplemental vitamin D and active forms of
vitaminD, and evaluatedboth dose and25(OH)Dcon-
centrations achieved for supplemental vitamin D.
Quality assessment
We examined the following methodological features
most relevant to the control of bias: randomisation;
Articles identified (n=164)
Potentially relevant articles identified
and screened for retrieval (n=32)
RCTs retrieved for more detailed evaluation (n=20)
Potentially appropriate RCTs to be
included in meta-analysis (n=17)
RCTs included in meta-analysis (n=10):
  Studied vitamin D2 or vitamin D3 (n=8)
  Studied active vitamin D (n=2)
Excluded by screening of titles and abstracts (n=132)
Excluded (n=12):
  Review article (n=10)
  Not an RCT (n=2)
RCTs excluded (n=3):
  Did not have fall outcome (n=1)
  Included patients who had experienced a stroke (n=1)
  Included intra-muscular vitamin D (n=1)
RCTs excluded from meta-analysis (n=7):
  Insufficient fall assessment (n=3)
  Open design or after acute hospitalisation (n=4)
(all 7 included in sensitivity analysis)
Fig 1 | Quorum flow chart. RCT=randomised controlled trial
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masking of treatment allocation; blinding; adherence;
and withdrawals.16 17 Given that vitamin D is available
over the counter, trials had to be double blind to be
included in the primary analysis. Open design trials
that met the general eligibility criteria were included
in the sensitivity analysis.
Differences in vitamin D assays
Interlaboratory and interassay variation limit com-
parison between trials for achieved 25(OH)D
concentrations,18 19 with competitive protein binding
assays tending to yield higher concentrations than
radioimmunoassays.20 To account for these variations,
we adjusted the 25(OH)D values from the two studies
where a competitive protein binding assay was used to
radioimmunoassay equivalent values, according to the
method described by Lips and colleagues.20
Statistical methods
Outcomeswere analysedon an intention to treat basis by
using random effect models.21 In addition, we calculated
the difference in relative risks to determine the number
needed to treat to prevent a person from falling.
Heterogeneity among studies was explored by prede-
fined covariates using the Q statistic as a test (significant
for P<0.10).22 The presence of heterogeneity suggests
that the studies should not be pooled because of signifi-
cant differences in results.23 In such cases, we explored
heterogeneity by dose of vitamin D and 25(OH)D con-
centration achieved by using visual inspection and ran-
dom effect meta-regression analysis. Additional
subgroup analyses undertaken for supplemental vitamin
D included type of vitamin D (D2v D3), gender, age (<
80 years v ≥80 years), treatment duration (<12months v
≥12months), level of independence (independent v insti-
tutionalised), and additional calcium supplementation.
To evaluate publication bias, we used Begg’s test and
Egger’s testwith all eight trials from the primary analysis
or all 15 trials from the sensitivity analysis.24 Statistical
analysis was performed with STATA version 8.0 (Stata-
Corp, College Station, TX, USA).
Box 1 Fall ascertainment in trials with supplemental vitamin D included in the primary
analysis
Broe et al, 2007w1
Falls were defined as “a sudden, unintentional change in position causing a resident to fall
on the ground.” Nursing staff filled out an incident report at the time of the event, the
primary care physician verified it, and the information was entered into the incident report
database.
Bischoff-Ferrari et al, 2006w2
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.” Participants were asked to send a postcard after every fall, which was then followed
by a telephone call from a staff member to assess the circumstances of the fall. In
addition, falls were ascertained at every follow-up visit (every six months).
Prince et al, 2008w3
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.” Patients were interviewed by study staff every six weeks via telephone or during
clinic visits. The number of falls that had occurred in the previous six weeks and the
associated features of the falls were recorded on a questionnaire.
Flicker et al, 2005w4
Falls were defined as “an event that results in a person coming to rest inadvertently on the
ground or other lower level.” Residential care staff recorded falls continuously in diaries,
and these were mailed monthly to the central study centre.
Pfeifer et al, 2008w5
A fall was defined as “falling on to the floor or ground, or hitting an object like a chair or
stair.” Not included as falls were controlled or intentional movements towards a chair or
bed or a near fall in which the participant caught oneself before falling on to the floor or
ground. The number of falls was recorded in fall diaries—each day the participants had to
make a cross in the diary depending on whether a fall had occurred or not. Every two
months, the study participants were also asked via telephone interviews whether a fall
had happened.
Bischoff et al, 2003w6
Falls were defined as “unintentionally coming to rest on the ground, floor, or other lower
level.” Coming to rest against furniture or a wall was not counted as a fall. Falls were
recorded by nurses on the inpatient units who had received training in the use of the fall
protocol (which included recording date, time, circumstances, and injuries).
Pfeifer et al, 2000w7
A fall was defined as “falling on to the floor or ground or hitting an object like a chair or
stair.”Not included as falls were controlled or intentionalmovements toward a chair or bed
or a near fall in which the participant caught herself before falling on to the floor or ground.
The number of falls was recorded by questionnaires throughout the trial period.
Graafmans et al, 1996w8
A fall was defined as “unintentionally coming to rest at a lower level or on the ground.”
Participants were asked to record in a diary any falls they had during a 28-week period.
Every week, participants registered whether or not they had fallen, as well as the location,
time, and circumstances of each fall.
Prince et alw3
Broe et alw1
Flicker et alw4
Bischoff-Ferrari et alw2
Pfeifer et alw5
Bischoff et alw6
Pfeifer et alw7
Combined
Broe et alw1
(200 IU D2/day)
Broe et alw1
(400 IU D2/day)
Broe et alw1
(600 IU D2/day)
Graafmans et alw8
Combined
Relative risk (95% CI)High dose vitamin D
0.5 0 50.1 10
Favours
supplemental
vitamin D
Favours
control
Low dose vitamin D
Pooled relative
risk (95% CI)
0.81 (0.71 to 0.92)
Pooled relative
risk (95% CI)
1.10 (0.89 to 1.35)
Fig 2 |Fall prevention with high dose (700-1000 IU a day) and
low dose (200-600 IU a day) of supplemental vitamin D. Boxes
represent relative risks, and the size of the boxes is
proportional to the size of the high dose supplemental
vitamin D trials included in the primary analysis. Error bars
represent 95% confidence intervals. Shaded boxes indicate
trials with vitamin D3, and white boxes indicate those with
vitamin D2
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RESULTS
A total of 164 articles were found in our initial search,
132 of which could be excluded by screening the titles
and abstracts (fig 1). A further 12 articles were
excluded either because they did not detail rando-
mised controlled trials or they were review articles.
Ten more trials were excluded because they did not
meet the inclusion criteria so that 10 randomised trials
were included in the final analysis—eight that studied
either vitamin D2 or vitamin D3 and two that assessed
active forms of vitamin D.
Trials assessing supplemental vitamin D
We identified eight randomised controlled trials of
supplemental vitamin D that met our inclusion criteria
(box 1).w1-w8 All trials assessed vitamin D treatment for
the prevention of falls as a primary or secondary out-
come and were identified through our MeSH term
Table 1 | Randomised controlled trials of supplemental vitamin D included in the primary analyses
Number of
participants
Age (years;
mean (SD))
Sample
population
Treatment
(daily dose)
Adher-
ence
Study duration
(months)
25(OH)D serum concentration (mmol/l; mean (SD))
Treatment group Control group Assay used
High dose trials
Broe et al, 2007w1 48
(36 women,
12 men)
89 (5) Nursing home
patients
800 IU vitaminD2 or placebo 98% 5 54 (23) to 75 (15)
at 5 months
(n=17). DiaSorin
equivalent mean
values:43to60at
5 months
53 (29) to 55-60
at 5 months
(n=20). DiaSorin
equivalent mean
values: 42 to 48
Competitive
protein binding
assay
Bischoff-Ferrari et
al, 2006 w2
445
(246 women,
199 men)
71 (5) Ambulatory
individuals
700 IU vitamin D3 + 500 mg
calcium (citrate malate) or
placebo
93% 36 76 (35) to 107
(38) at 36months
(n=182).DiaSorin
equivalent mean
values: 67 to 95
73 (32) to 72 (30)
at 36 months
(n=195). DiaSorin
equivalent mean
values: 65 to 64
Competitive
protein binding
assay
Prince et al,
2008w3
302 women 77 (5) Patients with
history of falling
recruited from
emergency
departments, the
electoral roll, and
receiving home
nursing services.
1000 IU vitaminD2 + 500mg
calcium (calcium carbonate)
or 500mgcalcium+placebo
86% 12 45 to 60 at
12 months
44.3 to 49 at
12 months
Radioimmunoas-
say
Flicker et al,
2005w4
625
(593 women,
32 men)
83 (8) Residental care
patients
Initially 10 000 IUD2 weekly,
then 1000 IU D2 + 600 mg
calciumor placebo+ 600mg
calcium (calcium carbonate)
68% 24 25-60 at
baseline: (89% of
participants). No
follow-up
25-60 at baseline
(89% of
participants). No
follow-up
Radioimmunoas-
say
Pfeifer et al,
2008w5
242
(121 women,
121 men)
77 (4) Ambulatory
individuals
800 IU vitaminD3 + 1000mg
calcium or 1000 mg calcium
+ placebo
80% 20 55.4 (18.5) to
84.5 (18.0) at
12 months
(n=122)
53.8 (18.4) to
56.6 (20) at
12 months
(n=120)
Radioimmunoas-
say
Bischoff et al,
2003w6
122 women 85 (7) Institutionalised
patients
800 IU vitaminD3 + 1200mg
calcium or 1200 mg calcium
+ placebo
100% 3 30.8 (23-55) to
65.5 (49.8-82.8)
at 3 months
(n=45)
29(23-55)to28.5
(24.5-41.5) at
3 months (n=44)
Radioimmunoas-
say
Pfeifer et al,
2000w7
137 women 74 (1) Community
dwelling
individuals
800 IU vitaminD3 + 1200mg
calcium or 1200 mg calcium
+ placebo
96% 2with treatment
plus 10 without
treatment
25.7 (13.6) to
66.1 (33.1) at
2 months (n=70)
24.6 (12.1) to
42.9 (33.1) at
2 months (n=67)
Radioimmunoas-
say
Low dose trials
Broe et al, 2007w1 51
(39 women,
12 men)
92 (6) Nursing home
patients
200 IU vitaminD2 or placebo 98% 5 45 (23) to 60 (20)
at 5 months
follow-up (n=24).
Diasorin
equivalent mean
values: 36 to 48
50 (23) to 61 (34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Broe et al, 2007w1 50
(38 women,
12 men)
88 (5) Nursing home
patients
400 IU vitaminD2 or placebo 98% 5 53 (28) to 55 (22)
at 5 months
(n=24). Diasorin
equivalent mean
values: 42 to 44
50 (23) to 61 (34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Broe et al, 2007w1 50
(37 women,
13 men)
89 (6) Nursing home
patients
600 IU vitaminD2 or placebo 98% 5 40 (19) to 60 (20)
at 5 months
(n=23). Diasorin
equivalent mean
values: 32 to 48
50 (23) to 61 (34)
at 5 months
(n=23). Diasorin
equivalent mean
values: 40 to 49
Competitive
protein binding
assay
Graafmans et al,
1996w8
354
(302 women,
52 men)
83 (6) Ambulatory
patients inhomes
and apartments
for older
individuals
400 IU vitamin D3 +
estimated calcium intake
from dairy products (800-
1000 mg/d)
85% 7 Not defined Not defined Not defined
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search. One study consisted of a multiple dose trial in
which the authors provided additional data for the four
trial arms (200, 400, 600, and 800 international units
(IU) D2v placebo).w1
Table 1 shows the characteristics of the eight double
blind randomised controlled trials with sufficient fall
assessment included in our study, including one rando-
mised controlled trial with four study arms.w1 The eight
trials involved 2426 individuals in total, 81% of whom
were women, and participants had an approximate
mean age of 80 years. All participants were in stable
health and were living in the community or in nursing
homes. Vitamin D3 was used in five studies and vita-
minD2 in three studies. VitaminD2 or D3 was given in
a daily dose ranging from 200 IU to 1000 IU. Treat-
ment duration varied from 2 months to 36 months.
Calcium supplementation was used in both treatment
and placebo groups in five randomised controlled
trials, and the dose varied between 500 mg/day and
1200 mg/day. In one study, calcium was provided
only in the treatment group, and vitamin D alone was
comparedwith placebo in two trials. Adherence varied
between 68% and 100%, with seven out of eight trials
reporting adherence of 80-100%.
Fall prevention with oral supplemental vitamin D
In the eight randomised controlled trials, the pooled
relative risk for any dose of vitamin D preventing a
fall was 0.87 (95% CI 0.77 to 0.99). However, hetero-
geneity in results was seen among studies (Q test:
P=0.05), although this was resolved after stratifying
trials by daily dose (200-600 IU v 700-1000 IU).
The pooled relative risk for the seven studies with
700-1000 IU supplemental vitaminD a day (1921 indi-
viduals) was 0.81 (95%CI 0.71 to 0.92) suggesting that
a high dose of vitamin D a day reduced the risk of a
person falling by 19% (table 2, fig 2). The pooled risk
difference for the high dose was 9.4% (95% CI 5.1% to
13.7%; P<0.0001), so the number needed to treat was
11 (95% CI 7 to 20) for a treatment duration of
2-36 months.
The pooled relative risk for the two trials with a dose
of less than 700 IU (200-600 IU) vitamin D a day was
1.10 (95% CI 0.89 to 1.35; Q test: P=0.42) indicating
that less than 700 IUvitaminDadaydid not reduce fall
risk (table 3, fig 2).
Achieved serum 25(OH)D concentrations of 60
nmol/l ormore resulted in a 23% fall reduction (pooled
relative risk 0.77, 95% CI 0.65 to 0.90), whereas con-
centrations of less than 60 nmol/l had no effect on
number of falls (pooled relative risk 1.35, 95% CI
0.98 to 1.84).
Figure 3 shows the relationship between vitamin D
and falls, and suggests that fall prevention beginswith a
daily dose of 700 IU supplemental vitamin D. This
threshold was confirmed in a meta-regression of 2426
Table 2 | Primary pooled analysis and primary subgroup analyses for high doses of supplemental vitamin D (700-1000 IU) and the prevention of falls
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/
total
treated
Number of
fallers/
total
control
Effect
relative
risk
Lower 95%
CI
Upper 95%
CI
Q test P
value I2
Fall
reduction
P value:
difference
between
subgroups
Broe et al, 2007w1 (800 IU D2) 48 5/23 11/25 0.49 0.21 1.16 — — — —
Bischoff-Ferrari et al, 2006w2 (700 IU D3) 445 107/219 124/226 0.89 0.74 1.07 — — — —
Prince et al, 2008w3 (1000 IU D2) 302 80/151 95/151 0.84 0.69 1.02 — — — —
Flicker et al, 2005w4 (1000 IU D2) 625 170/313 185/312 0.92 0.80 1.05 — — —
Pfeifer et al, 2008w5 (800 IU D3) 242 48/121 76/121 0.63 0.49 0.81 — — — —
Bischoff et al, 2003w6 (800 IU D3) 122 14/62 18/60 0.75 0.41 1.37 — — — —
Pfeifer et al, 2000w7 (800 IU D3) 137 11/70 19/67 0.55 0.29 1.06 — — — —
Primary pooled analysis 1921 435/959 528/962 0.81 0.71 0.92 0.12 41% -19% —
Primary subgroup analyses
D3 only (w2,w6,w5,w7) 946 180/472 237/474 0.74 0.58 0.93 0.12 49% -26%
0.28
D2 only (w1
(800),w3,w4) 975 255/487 291/488 0.88 0.77 1.00 0.32 12% -12%
Men only (w1(800),w2) 211 51/105 52/106 0.99 0.75 1.31 0.58 0% -1%
0.34
Women only* 1468 336/733 400/735 0.85 0.76 0.95 0.36 9% -15%
D3 women (w2,w6,w7) 505 84/253 112/252 0.78 0.63 0.95 0.55 0% -22%
0.27
D2 women (w1
(800),w3,w4) 963 252/480 288/483 0.87 0.74 1.03 0.21 35% -13%
Age 65-79 and/or independent (w2,w3,w5,w7) 1126 246/561 314/565 0.77 0.65 0.93 0.10 52% -23%
0.46Age 80+ and/or institutionalised (w1(800),w4,
w6)
795 189/398 214/397 0.86 0.70 1.07 0.32 13% -14%
Less than 12 months’ treatment duration
(w1(800),w6,w7)
307 30/155 48/152 0.62 0.42 0.91 0.67 0% -38%
0.07
At least 12 months’ treatment duration (w2,w3,
w4,w5)
1614 305/804 480/810 0.83 0.72 0.96 0.09 56% -17%
Maineffect vitaminD (w1(800),w3,w4,w5,w6,w7) 1476 327/740 404/736 0.77 0.65 0.92 0.09 48% -23% —
Subgroups with at least two available trials are presented.
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
*Given that the Flicker et al trial included only 5% men, we added the total study population finding of Flicker to the female subgroup.
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individuals, in which a significant inverse relationship
was found between dose and the risk of sustaining at
least one fall (beta estimate for dose: ≥700 IU v <700
IU=−0.337; P=0.02). Figure 3 also suggests that a 25
(OH)D concentration of 60 nmol/l is required for fall
prevention. This possibility was likewise confirmed by
a meta-regression of 1447 individuals (two trials did
not provide 25(OH)D dataw4 w8), which indicated a sig-
nificant inverse relationship between 25(OH)D serum
concentration and the risk of sustaining at least one fall
(beta estimate for 25(OH)D concentration: ≥60 nmol/l
v <60 nmol/l=−0.586; P=0.005).
Primary subgroup analyses with trials assessing high doses
of supplemental vitamin D
In subgroup analyses of the trials that assessed a high
dose of supplemental vitamin D (700-1000 IU), the
pooled relative risk reduction was 12% in trials that
used vitamin D2 compared with 26% for trials that
used vitamin D3 (P=0.28; table 2). The combined
effect of calcium plus vitamin D compared with pla-
cebo in one study showed a relative risk reduction of
19%.w2 The main effect of vitamin D, either vitamin D
compared with placebo or vitamin D plus calcium
compared with calcium only, was tested in six studies.
The pooled relative risk reduction for these six studies
was 23% (relative risk 0.77, 95% CI 0.65 to 0.92); thus,
the main effect of vitamin D may not depend on addi-
tional calcium supplementation. The effect of vitamin
D in women was tested in six studies (n=1468), which
had a pooled relative risk reduction of 15% compared
with 19% in men and women combined. Data on men
from two trials (n=211) were limited.w1 w2 Treatment
duration did not modulate the effect of vitamin D sig-
nificantly: fall reduction was 38% with a treatment
duration of less than 12 months in three small trials
(relative risk 0.62, 95% CI 0.42 to 0.91) compared
with 17% with a treatment duration of 12 months or
more in four larger trials (relative risk 0.83, 95% CI
0.72 to 0.96; P=0.07). The benefits of 700-1000 IUvita-
min D a day on risk of falls were present in both ambu-
latory and institutionalised older individuals, as well as
in trials with a mean age 65-79 years or higher.
Sensitivity analysis of supplemental vitamin D
In a sensitivity analysis, we examined the effect size for
supplemental vitamin D when including studies
meeting less stringent quality criteria. Seven studies
were identified for the sensitivity analysis,w9-w15 six
through our MeSH term search and one in the
abstracts of the American Society for Bone and
Mineral Research (table 4).w12 Three of these trials
Table 3 | Primary pooled analysis for low doses of supplemental vitamin D (<700 IU) and the prevention of falls
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative risk
Lower
95% CI
Upper
95% CI
Q test
P value I2 Fall reduction
Broe et al, 2007w1(200) (200 IU D2) 51 15/26 11/25 1.31 0.76 2.27 — — —
Broe et al, 2007w1(400) (400 IU D2) 50 15/25 11/25 1.36 0.79 2.35 — — —
Broe et al, 2007w1(600) (600 IU D2) 50 15/25 11/25 1.36 0.79 2.35 — — —
Graafmans et al, 1996w8 (400 IU D3) 354 62/177 66/177 0.94 0.71 1.24 — — —
Primary pooled analysis
(w1(200,400,600),w8)
505 107/253 99/252 1.10 0.89 1.35 0.42 0% +10% (ns)
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
ns=not significant.
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Fig 3 |Fall prevention by dose and achieved 25(OH)D
concentrations. Circles represent relative risks and error bars
represent 95% confidence intervals. Trendline is based on
series of effect sizes (circles). There were three trials with 800
IU D3,
w5 w6 w7 so the effect size for 800 IU D3 is the pooled
result from these three trials. Likewise, the effect size for
1000 IU D2 is the pooled result from the two trials with 1000
IU D2.
w3 w4 We have listed the same dose D2 and D3 separately
in the graph to account for their potential different impact on
fall reduction. As there were two data points from the Broe et
al trial that reached 48 nmol/l,w1 two trials that reached 60
nmol/l,w1 w3 and two trials that reached 66 nmol/l,w6 w7 we
pooled each of the sets. On the basis of visual inspection of
figure 3, the benefits of vitamin D for fall risk started at a dose
of 700 IU a day
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were excluded from the primary analysis for their
insufficient assessment of falls,w9-w11 with incomplete
fall assessment for the entire trial period in two stu-
dies.w9 w10 Three trials had an open study design and
were not blinded,w12 w13 w14 and one trial enrolled
patients in unstable health states.w15
The pooled effect of all 15 eligible trials including
17 786 individuals of any dose and any quality fall
assessment suggested a non-significant 7% fall reduc-
tion with vitamin D (relative risk 0.93, 95% CI 0.87 to
1.01). However, variation among the 15 trials was lar-
ger than expected (Q test: P=0.009).
After adding the seven randomised controlled trials
that did notmeet our criteria for the primary analysis to
the seven trials originally included the primary analy-
sis, the pooled relative risk for the high dose of supple-
mental vitamin D (700-1000 IU vitamin D a day) was
0.92 (95% CI 0.85 to 0.99; total 17 281 individuals;
table 5). However, variation among the 14 trials was
larger than expected (Q-test: P=0.006), suggesting that
adding the lower quality trials to the analysis intro-
duces heterogeneity.
Trials of oral active forms of vitamin D
We found two randomised controlled trials of active
forms of vitamin D that met our inclusion criteria
(table 6).w16 w17 Falls were addressed as a primary out-
come measure in both studies. No additional trials
were identified for a sensitivity analysis. The two trials
included 624 individuals with a mean age of 73 years,
70% of whomwere women. In both studies, patients in
the treatment group were more likely to experience
hypercalcaemia (up to 3 mmol/l) than were those in
the control group. The incidence of hypercalcaemia
was twice as frequent in the treatment group as in the
placebo group in one trial (12% v 6%),25 without details
in the other. 26 The pooled relative risk for fall preven-
tion for active forms of vitamin D was 0.78 (95% CI
0.64 to 0.94), and active forms of vitamin D reduced
the risk of falls by 22% (table 7).
Fall prevention with active forms of vitamin D compared
with high dose supplemental vitamin D
The pooled relative risk for fall prevention of 0.78 for
active forms of vitamin D was similar to the pooled
relative risk of 0.81 for high dose of supplemental vita-
min D. The ratio of the two effect sizes (pooled relative
risk supplemental vitamin D/pooled relative risk
active forms of vitamin D) was 1.04 (95% CI 0.84 to
1.31), suggesting that active forms and standard forms
of vitamin D have statistically indistinguishable effects
on fall prevention.
Test for publication bias
We found no evidence for publication bias in the eight
supplemental vitamin D trials, according to both
Begg’s test and Egger’s test.24 Although the Begg’s
test funnel plot indicated a potential absence of nega-
tive studies with small sample sizes, a trim and fill ana-
lysis did not confirm this possibility.27 28
Table 4 | Trials of supplemental vitamin D excluded from the primary analyses but included in sensitivity analyses
Source
Reason for
exclusion
Number of
participants
Age (years;
mean (SD)) Sample population
Treatment
(daily dose) Adherence
Studyduration
(months)
25(OH)D serum concentration
(mmol/l; mean (SD))
Treatment
group Control group
Grant et al,
2005w9
Insufficient fall
assessment
5292
(4481 women,
811 men)
77 (6) Individuals who
were mobile before
developing a low
trauma fracture
800 IU vitamin D3
with or without
1000 mg calcium
(calcium carbonate)
47% 24 38 (16) to 62
(19.5) at
12 months
38 (16) to 45.8
(18) at
12 months
Trivedi et al,
2003w10
Insufficient fall
assessment
2686
(2037 men,
649 women)
75 (5) Community dwelling
individuals
800 IU vitamin D3
(100 000 IU every
4 months) or
placebo
80% 60 74.3 (20.7) at
48 months
53.4 (21.1) at
48 months
Chapuy et al,
2002w11
Insufficient fall
assessment
583 women 85 (7) Ambulatory
individuals living in
apartment houses
for elderly persons
800 IU vitamin D3 +
1200 mg calcium
(tri-calcium
phosphate) or
placebo
95% 24 21.3 (13.3) to
77.5 at
24 months
22.8 (17.3) to 15
frombar graphat
24 months
Kärkkäinen et al,
2007w12
Open study
design
3432 women 67 Community dwelling
individuals
800 IU vitamin D3 +
1gcalciumorcontrol
group (no placebo)
Adherence not
stated
36 Not done Not done
Law 2 et al,
006w13
Open study
design
3717
(2788 women,
929 men)
85 Patients living in
residential
accommodation
1100 IU vitamin D2
(100 000 IU
ergocalciferol every
3 months) or no
treatment (no
placebo)
Adherence not
stated
10 47 (35-102) to
74 (52-110) at
3 months
Not done
Harwood et al,
2004w14
Open study
design
76 women 82 (67-92) Patients in
rehabilitationwards,
previously
community dwelling
800 IU vitamin D3 +
1gcalciumorcontrol
group (no placebo)
Adherence not
stated
12 30 (6-75), to 50
at 12 months
30 (12-64), to 27
at 12 months
Latham et al,
2003w15
Patients in
unstable health
243
(129 women,
114 men)
80 (77-81) Patients in acute
care for any reason
1600 IU vitamin D2
(300000 IUassingle
dose) or placebo
100% 6 37.5 (35-45) to
60 at 3 months
47.5 (40-52.5) to
47.5 at 3months
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DISCUSSION
In this meta-analysis of eight double blind randomised
controlled trials, the efficacy of supplemental vitamin
D for fall prevention depended on dose and achieved
25(OH)D concentrations among individuals aged
65 years and older. No fall reduction was observed
for a daily dose of less than 700 IU vitamin D or
achieved serum 25(OH)D concentrations below 60
nmol/l. Daily vitamin D doses in the range of 700 IU
to 1000 IU or achieved serum concentrations between
60 nmol/l and 95 nmol/l reduced the risk of falling by
19%. Given the absence of data beyond these benefi-
cial ranges, our analyses don’t preclude the possibility
that higher doses of vitamin D or higher achieved 25
(OH)D concentrations would have been even more
efficient in reducing falls. At the high dose range of
700 IU to 1000 IU a day, the benefit of vitamin D was
not significantly affected by type of supplemental vita-
minD, gender, age, or level of independence.Notably,
fall prevention with a high dose might not depend on
additional calcium supplementation and was attained
with treatment for less than 12 months (2-5 months).
The benefit was sustained for 12-36 months.
An important risk factor for falls is muscle weakness,
which is a prominent feature of the clinical syndrome
of vitamin D deficiency and could plausibly mediate
fracture risk through increasing susceptibility to
falls.29 Binding of vitamin D to its nuclear receptor in
muscle tissue may lead to de novo protein
synthesis,29 30 a benefit that appears to precede the
effect of vitamin D on bone.2
Comparison with other studies
Our findings confirm those in an earlier meta-analysis
on falls from 2004,10 which showed that any vitamin D
reduced falls in older individuals by 22%. Of three
trials with supplemental vitaminD included in this ear-
lier meta-analysis, one trial of 400 IU vitamin D a day
showed a neutral effect,w8 whereas two trials with 800
IU a day suggested a beneficial effect on risk of falls
(odds ratio 0.65, 95% CI 0.40 to 1.00).w6 w7 Since then,
five doubleblind trialswith sufficient quality fall assess-
ment have been performed.w1 w2 w3 w4 w5 Our meta-
analysis including these trials confirmed a benefit of
700 IU to 1000 IU vitamin D a day. Lending further
support to our findings, several double blind rando-
mised controlled trials have documented fracture pre-
vention with 700-800 IU vitaminD a day,12 31 32 but not
with 400 IU a day.33-35
We found a 38% reduction in the risk of falling for
the high dose range of vitamin D with treatment for
2-5 months, and a sustained 17% fall reduction with
treatment for 12-36 months. Indirect support for a
rapid and sustained effect of vitamin D on falls comes
from the large fracture trial by Chapuy and
colleagues.36 Although falls were not assessed in this
trial, supplementationmost likely reduced the number
of falls, leading to the reduction in fracture risk appar-
ent after six months.
Fall reduction was assessed as one of the end points
in a 2007 evidence report on vitamin D commissioned
by the United States Department of Health and
Human Services.37 The authors combined nine
blinded and two open design trials (n=13 888) of any
oral dose of vitamin D (D2 and D3) with or without
calcium compared with calcium or placebo. Their
pooled result suggested a non-significant 8% reduction
in falls with vitamin D (odds ratio 0.92, 95%CI 0.85 to
1.00). Heterogeneity by dose was not detected. The
result of the evidence report is consistent with our sen-
sitivity analysis of all 15 eligible trials regardless of vita-
min D dose and quality of fall assessment: we found a
non-significant 7% fall reduction with vitamin D in
17 786 individuals. Variation among the 15 trials was
larger than expected (Q test: P=0.009), however, even
for the high dose sensitivity analysis (Q test: P=0.006).
Table 5 | Sensitivity analysis of the seven high dose trials from the primary analysis and the seven eligible high dose trials that did not meet the criteria for
the primary analysis
Study (daily dose of vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative risk
Lower
95% CI
Upper
95% CI
Q test
P value I2 Fall reduction
Pooled primary analysis of the seven
high dose trials (w1(800),w2,w3,w4,
w5,w6,w7)
1921 435/959 528/962 0.81 0.71 0.92 0.12 41% -19%
Sensitivity analysis including the seven high dose trials that did not meet criteria for primary analysis
Grant et al, 2005w9 (800 IU D3) 5292 380/2649 381/2643 1.00 0.87 1.14 — — —
Trivedi et al, 2003w10 (800 IU D3) 2038 254/1027 261/1011 0.96 0.83 1.11 — — —
Chapuy et al, 2002w11 (800 D3) 583 251/393 118/190 1.03 0.90 1.17 — — —
Kärkkäinenet al, 2007w12 (800 IUD3) 3432 180/1718 209/1714 0.86 0.71 1.04 — — —
Law et al, 2006w13 (1100 IU D2) 3717 770/1762 833/1955 1.03 0.95 1.10 — — —
Harwood et al, 2004w14 (800 IU D3) 76 7/39 13/37 0.51 0.23 1.11 — — —
Latham et al, 2003w15 (1600 IU D2) 222 64/108 60/114 1.13 0.89 1.42 — — —
Pooled sensitivity analysis (w1(800),
w2,w3,w4,w5,w6,w7,w9,w10,w11,
w12,w13,w14,w16)
17 281 2341/8655 2403/8626 0.92 0.85 0.99 0.006 56% -8%
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
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A 2007 meta-analysis that focused on vitamin D3
found a 12% reduction in falls by pooling four trials
irrespective of their vitamin D dose or quality of fall
assessment.38 Our analysis of five trials with sufficient
quality fall assessment showed that high doses of vita-
min D3 reduced falls by 26%.
We addressed the additional importance of calcium
in our primary analysis of high dose trials and docu-
mented a 23% fall reduction on the basis of results
from six high quality trials of vitamin D alone
compared with placebo or vitamin D plus calcium
compared with calcium.w1 w3-w7 VitaminD in combina-
tion with calcium comparedwith placebo reduced falls
by 19% according to limited data from one trial.w2
Thus, the effect of 700-1000 IU vitamin D a day on
falls may not depend on additional calcium supple-
mentation, which could be explained by the calcium
sparing effect of vitamin D.39 40
Active forms of vitamin D reduced falls by 22% and
the high dose supplemental vitamin D reduced falls by
19%, suggestingnodifference in efficacybetween these
alternatives in unselected older persons. However, the
efficacy data for active forms of vitamin D was drawn
from relatively few studies. In addition, active forms
cost more and have a higher risk profile, so we believe
adequate dosing of supplemental vitamin D should be
preferred. Importantly, the efficacy of active forms of
vitamin D adds to the evidence that improved vitamin
D status reduces the risk of falling in older individuals.
Limitations of study
As with all meta-analyses, this review has the potential
for publication bias. However, we found no evidence
for publication bias using the Begg’s test and the
Egger’s test with all eight trials.24 Although the Begg’s
test funnel plot suggested a possible absence of nega-
tive studies with small sample sizes, the trim and fill
analysis did not confirm this suggestion.27 28 With
respect to trial quality, our primary analysis was
restricted to trials with a double blind design and suffi-
cient quality fall assessment to address the efficacy of
vitaminD for fall prevention. In our sensitivity analysis
that included additional trials with an open study
design or insufficient fall assessment, study variation
was larger than expected for the pooled result from
all 15 trials. Even within the 14 high dose trials, varia-
tion between trials was larger than expected, support-
ing our pre-defined strategy of focusing on fall efficacy
from double blind trials with sufficient fall assessment.
Implications for future research
We found a greater fall reduction in studieswith amax-
imum vitamin D daily dose of 1000 IU a day than in
studies with lower doses; therefore, higher doses may
be evenmore effective. Such doses should be explored
in future research to optimise the fall prevention ben-
efit with vitamin D.
Conclusions
Doses of 700 IU to 1000 IU supplemental vitamin D a
day could reduce falls by 19% or by up to 26% with
vitamin D3. This benefit may not depend on additional
calcium supplementation, was significant within
2-5 months of treatment, and extended beyond
12 months of treatment. Conversely, our results do
not support the clinical use of vitamin D doses below
700 IU a day for the prevention of falls among older
individuals. A 25(OH)D concentration of at least 60
nmol/l is required for fall prevention; therefore, a
daily intake of at least 700 IU supplemental vitamin D
iswarranted inall individuals age65andolder.Notably,
good adherence is essential as the effect of vitaminDon
falls will not be proportional below 700 IU a day.
Furthermore, it is possible that greater benefits may be
Table 6 | Randomised controlled trials of active forms of vitamin D included in the primary analyses
Source
Number of
participants
Age (years;
mean (SD))
Sample
population
Treatment (daily
dose) Adherence
Study
duration
(months)
25(OH)D serum concentration
(mmol/l; mean (SD))
Treatment group Control group
Dukas et al, 2004w16 278
(191 women,
187 men)
75 (5) Community
dwelling
individuals
1 μg 1α-
hydroxyvitamin D3
or placebo
84% among women,
87% among men
9 78.0 (21.6) to 60.7
(19.7) at 9 months
70.8 (26.8) at baseline
at 9 months
Gallagher et al,
2001w17
246 women 71 (4) Community
dwelling
individuals
0.5 μg 1,25-
dihydroxyvitamin D3
or placebo
70% 36 74.8 (29.0) to 55.5
(20.5) at 36 months
80.5 (27.4) to 63.2
(19.7) at 36 months
Table 7 | Primary pooled analysis for active forms of vitamin D and the prevention of falls
Study (daily dose of
vitamin D)
Number of
participants
Number of
fallers/total
treated
Number of
fallers/total
control
Effect
relative
risk
Lower
95% CI
Upper
95% CI
Q test P
value I2
Fall
reduction
Dukas et al, 2004w16
(1α-hydroxyvitamin D3)
378 40/192 46/186 0.84 0.58 1.22 — — —
Gallagher et al, 2001w17
(1,25-dihydroxyvitamin D3)
246 59/123 78/123 0.76 0.60 0.95 — — —
Pooled primary analysis
(w16,w17)
624 99/315 124/309 0.78 0.64 0.94 0.63 0% -22%
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.
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achieved with the use of vitamin D3 instead of vitamin
D2. Finally, active forms of vitamin D do not appear to
be more effective than 700-1000 IU of supplemental
vitamin D for fall prevention in older persons.
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